Hepatic alteration after treatment using tolvaptan.
Cabello Muriel
A
A
Marín Pozo
J F
JF
Alcalá Sanz
A
A
Carrillo Ortiz
D
D
D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D065092:Antidiuretic Hormone Receptor Antagonists; D001219:Aspartate Aminotransferases / Q000097:blood; D001552:Benzazepines / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000209:etiology*; D017809:Fatal Outcome; D006801:Humans; D007010:Hyponatremia / Q000188:drug therapy*; D007177:Inappropriate ADH Syndrome / Q000097:blood / Q000150:complications*; D008113:Liver Neoplasms / Q000097:blood / Q000150:complications / Q000556:secondary*; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D010257:Paraneoplastic Syndromes / Q000097:blood / Q000150:complications*; D000077602:Tolvaptan; D005723:gamma-Glutamyltransferase / Q000097:blood
D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D000077602:Tolvaptan; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase